Revolution Medicines (NASDAQ:RVMD) COO Margaret Horn Sells 3,575 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 3,575 shares of Revolution Medicines stock in a transaction on Monday, June 16th. The shares were sold at an average price of $156.12, for a total value of $558,129.00. Following the sale, the chief operating officer directly owned 154,647 shares of the company’s stock, valued at $24,143,489.64. This represents a 2.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $157.77 on Thursday. The firm has a market capitalization of $33.54 billion, a price-to-earnings ratio of -22.32 and a beta of 1.40. Revolution Medicines, Inc. has a 52-week low of $34.00 and a 52-week high of $166.50. The stock has a fifty day moving average of $144.38 and a 200 day moving average of $112.39. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the prior year, the company earned ($1.13) earnings per share. On average, research analysts expect that Revolution Medicines, Inc. will post -7.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after acquiring an additional 1,056,792 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Revolution Medicines by 194.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,289 shares of the company’s stock valued at $1,696,000 after acquiring an additional 14,062 shares during the last quarter. Raiffeisen Bank International AG bought a new stake in shares of Revolution Medicines in the 3rd quarter valued at about $921,000. Mass General Brigham Inc bought a new stake in shares of Revolution Medicines in the 4th quarter valued at about $27,407,000. Finally, M&T Bank Corp bought a new stake in shares of Revolution Medicines in the 4th quarter valued at about $52,723,000. Institutional investors own 94.34% of the company’s stock.

Analysts Set New Price Targets

RVMD has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Tuesday, April 21st. Evercore reissued an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday, April 14th. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research note on Monday, June 1st. HC Wainwright lifted their price target on Revolution Medicines from $169.00 to $195.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Revolution Medicines in a research note on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $123.72.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.